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The requirement for interferon-g (IFNg) in resolution of an HSV-2 vaginal infection and the cellular sources of this cytokine
in the vaginal mucosa were assessed. IFNg levels in vaginal secretions peaked on Days 2 and 5 following HSV-2 inoculation.
Natural killer (NK) cell depletion greatly diminished the early production of IFNg but had no significant effect on the rate
of virus clearance. CD4/ T cells were primarily responsible for the second peak of IFNg levels and neutralization of this
IFNg beginning 3 days after virus inoculation delayed, but did not prevent, virus clearance from the vagina. HSV-2 persisted
in mice depleted of both CD4/ and CD8/ T cells while clearance was delayed in CD4/, but not CD8/ T cell-depleted mice,
demonstrating the T cell dependence and predominant role of CD4/ T cells in resolution of the infection. Together, these
data suggest that IFNg is not essential for virus clearance but plays an important role in enhancing T cell-mediated clearance
mechanisms. The implication of these results is that IFNg produced locally in the genital tract enhances virus clearance
and may ultimately be important for reducing the amount of virus available to infect sensory ganglia. q 1997 Academic Press
INTRODUCTION the presence of interferon-g (IFNg) (Smith et al., 1994).
Similarly, HSV-1 persisted in the eyes of mice with a
Herpes simplex virus type 2 (HSV-2) infects both the targeted deletion of the IFNg gene as compared to wild-
oral and genital mucosa of humans. In addition to initial type littermates in a model of herpetic stromal keratinitis
replication and primary disease at the site of infection, (Bouley et al., 1995).
the virus can ascend sensory neurons, replicate, and The immune mechanisms responsible for clearing
become latent in the sensory ganglia. Reactivation of HSV-2 from the genital mucosa have not been well
latent virus can result in recurrent disease at the site of studied. Protection of mucosal surfaces is generally
initial infection. In addition to the pain associated with thought to be a function of secretory IgA. However, for
HSV infections, the lesions associated with primary and pathogens such as HSV which can spread intracellu-
recurrent disease at the mucosal surface may also serve larly, cellular immune mechanisms are required for
as efficient portals of entry for other sexually transmitted resolution of infection. It has been shown that adoptive
diseases. transfer of T lymphocytes from the draining lymph
Clearance of virus from infected tissue is most often nodes of HSV-infected mice protected naive recipients
T cell-mediated and involves both cytokine-mediated ef- from a lethal challenge of the genital mucosa with HSV-
fector mechanisms and direct cytotoxic effects on virus- 2 (McDermott et al., 1989). More recently, it was shown
infected cells. Clearance of acute HSV infections can be that intravaginal inoculation with an attenuated strain
accomplished by either CD4/ or CD8/ T cells depending of HSV-2 resulted in the influx of HSV-specific Th 1-
on variables such as virus dose, tissue site, or mouse type CD4/ T cells into vaginal tissue (Milligan and
strain (Nash et al., 1987; Wildy and Gell, 1985; Leung et Bernstein, 1995a), which apparently coincided with the
al., 1984). A recent study using mice lacking CD4/ or rapid resolution of the infection. In the current study,
CD8/ T cells as a result of targeted gene deletions dem- a murine model of genital HSV-2 infection was used
onstrated that effective clearance from the skin was de- to examine the role of IFNg in clearance of HSV-2 from
pendent mainly on CD4/ T cells (Manickan and Rouse, the vaginal mucosa. Intravaginal inoculation with HSV-
1995). In a cutaneous model of HSV-1 infection using 2 resulted in sequential production of IFNg by NK cells
genetically resistant mice, virus clearance could be ef- then T lymphocytes; however, only IFNg produced pri-
fected by either T cell subset and was dependent on marily by T cells after Day 3 played a role in rapid
clearance of virus from the genital tract. The results of
this study suggest that IFNg was not essential for the1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (513) 559-7655. ultimate clearance of virus from the vaginal mucosa
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but was important for increasing the effectiveness of at 0707 until plaque titration on Vero cell monolayers as
described previously (Milligan and Bernstein, 1995b).T cell-dependent mechanisms of virus clearance.
In vivo depletion of T cell subsets and neutralizationMATERIALS AND METHODS
of IFNg
Mice
Mice were injected intraperitoneally (i.p.) with 1.5 mg
Female BALB/cAnNHsd (Harlan–Sprague–Dawley, purified GK1.5 or 2.43 antibodies on Days 5,4,2, and 1
Inc., Indianapolis, IN) were used between 6 and 15 prior to HSV-2 inoculation, on the day of inoculation, and
weeks of age. Age-matched, uninoculated mice were every other day thereafter to Day 6. Mice treated with a
used as controls. mixture of 1.5 mg each of GK1.5 and 2.43 were treated
to Day 8. Splenic and gLN lymphocytes from antibody-
Virus
treated and control-treated mice were analyzed on the
day of inoculation by flow cytometry to determine in vivoThe bromodeoxyuridine-resistant mutant, HSV-2 333
tk0 (Stanberry et al., 1985), was grown and titered as depletion. GK1.5 antibody treatment typically resulted in
80–87% depletion of CD4/ gLN T cells and treatmentdescribed previously (Milligan and Bernstein, 1995b).
HSV-2 strain 186 was obtained from Dr. Lawrence Stan- with 2.43 antibody typically resulted in complete (100%)
CD8/ T cell depletion. Treatment with a cocktail of GK1.5berry (Children’s Hospital Medical Center, Cincinnati,
OH) and used as a challenge virus in these studies as and 2.43 antibodies resulted in an 87% depletion of
splenic CD3/ lymphocytes. In preliminary experiments,described previously (Milligan and Bernstein, 1995b).
virus clearance in mice treated with PBS or an irrelevant
Antibodies rat IgG monoclonal antibody was not different, therefore
PBS was used as a control treatment in these studies.Rabbit anti-asialo GM1 was purchased from Wako
IFNg was neutralized in vivo by daily i.p. injection ofChemicals USA, Inc. (Richmond, VA). Hybridomas 2.43
1.5 mg purified XMG1.2 antibody from the day prior to(anti-murine CD8), GK1.5 (anti-murine CD4), R46A2 (anti-
inoculation through Day 7 after inoculation. In some ex-murine IFNg), and HO2.2 (anti-murine CD8) were ob-
periments, treatment of mice was performed on Days 3tained from the American Type Culture Collection (Rock-
through 7 after inoculation. NK cells were depleted byville, MD). Hybridoma XMG1.2 (anti-murine IFNg) was
intravenous injection of 50–75 ml of rabbit anti-asialoobtained with permission of Dr. Tim Mosmann (Univ. of
GM1 antibody (dosage based on manufacturer’s antibodyAlberta, Alberta, Canada). Hybridomas were grown to log
titration) 2 days before and 1 day following intravaginalphase in RPMI supplemented with 20% fetal calf serum
inoculation with HSV-2 tk0.(FCS) (GIBCO Life Technologies, Gaithersburg, MD) and
then seeded into 150-cm2 flasks containing Hybridoma
Depletion of T lymphocyte subsets in vitro
Serum Free Media (GIBCO Life Technologies). After 5–
7 days, cells were removed by centrifugation and anti- CD4/ or CD8/ T cells were depleted as described
previously (Milligan and Bernstein, 1995a) with optimalbody was precipitated from supernatants with ammo-
nium sulfate (Sigma, St. Louis, MO), dissolved in distilled dilutions of GK1.5 or HO2.2 antibody, respectively, and
low tox M rabbit complement (Cedarlane Laboratories,water, and dialyzed extensively against phosphate-buf-
fered saline (pH 7.2). Antibody purification was monitored Ltd., Hornby, Ontario, Canada). Cells were washed three
times and counted prior to culture.by SDS–PAGE and antibody concentration was deter-
mined by UV spectrometry.
IFNg ELISPOT assay
Genital herpes inoculation and vaginal virus titration
A modification of the procedure described previously
(Milligan and Bernstein, 1995a) was used in these stud-Mice were inoculated intravaginally with HSV-2 333 tk0
or HSV-2 186 by a modification of the method described ies. Briefly, single cell suspensions of gLN lymphocytes
from uninoculated and HSV-2 tk0-inoculated mice werepreviously (Milligan and Bernstein, 1995b). Briefly, mice
which had been treated twice in a 1-week period with resuspended to 106 cells/ml in RPMI supplemented with
10% FCS. One hundred microliters of this cell suspension6a-methyl-17a-hydroxyprogesterone acetate (Sigma) at
3 mg/mouse were preswabbed with a cotton pledget, and a series of threefold dilutions was plated in duplicate
on nitrocellulose filter plates (Millipore Corp., Bedford,anesthetized with sodium pentobarbital, and inoculated
with 20 ml of virus suspension (5 1 105 –106 PFU HSV-2 MA) coated previously with 10 mg/ml purified R4-6A2
antibody. Plates were incubated overnight at 377, washed333 tk0; 106 PFU HSV-2 186) soaked onto a type 2 calgis-
wab. Vaginal virus titers were monitored by swabbing thoroughly to remove cells, and incubated with rabbit
anti-murine IFNg (Biosource International, Camarillo, CA)the vagina with a moist type 2 calgiswab which was
immediately added to 1.0 ml media followed by storage followed by peroxidase-conjugated goat anti-rabbit IgG
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(United States Biochemical Corp., Cleveland, OH). Plates was neutralized in vivo by daily treatment of mice with
anti-IFNg antibody beginning the day prior to HSV-2 tk0were then washed and developed with 3-amino-9 ethyl-
carbazole substrate and peroxide. Spots representing infection. IFNg was detected by ELISA in vaginal washes
from control-treated but not in anti-IFNg-treated micespecific cytokine-secreting cells were counted with the
aid of a dissecting microscope. through Day 9 postinoculation (Table 1). No significant
differences in vaginal virus titers of control-treated and
IFNg ELISA anti-IFNg-treated mice were observed through the first
IFNg was detected in vaginal secretions by washing 3 days of infection (Fig. 2A). Control-treated mice rapidly
the vagina twice with 60 ml Hank’s balanced salt solution cleared virus beginning on Day 4 while virus titers de-
plus 5% FCS. The wash was clarified by microcentrifuga- creased more slowly in anti-IFNg-treated mice (Fig. 2A),
tion and stored at0707 until quantitation by ELISA. ELISA resulting in an ultimate delay in viral clearance of approx-
plates were coated with purified R4-6A2 (anti-murine imately 2 days.
IFNg) at 5 mg/ml and blocked with PBS plus 5% bovine To determine if the IFNg produced during the first 3
serum albumin. A series of twofold dilutions of rIFNg days of infection was sufficient to effect the rapid clear-
standards (Sigma) at concentrations from 125 to 0.12 ance of virus from the vagina, anti-IFNg treatment was
Units/ml and undiluted vaginal washes were plated in initiated 3 days after genital inoculation at a time coinci-
duplicate and incubated overnight at 47. Plates were then dent with the end of the NK cell IFNg production (Days
washed and developed with the same reagents as for 2–3) but before T cell-mediated IFNg production began
IFNg ELISPOT plates except that o-phenylenediamine (Days 4–7). No significant differences in the kinetics of
dihydrochloride (OPD)/peroxide (Sigma) was used as the virus clearance from the vagina were observed between
substrate. The limit of detection of the assay was consid- control-treated and anti-IFNg-treated mice through the
ered to be the last concentration of rIFNg standard which first 4 days of infection (Fig. 2B). However, viral titers
gave an OD490 value greater than the mean plus 3 stan- were significantly elevated in treated mice on Days 5–7
dard deviations of the background (media alone) wells. and, similar to the previous experiment (Fig. 2A), clear-
ance was delayed by about 2 days.Statistical analysis
Data were analyzed by unpaired, two-tailed t tests or Clearance of HSV-2 from the vaginal mucosa requires
one-way analysis of variance with the Bonferroni correc- T cells but not NK cells
tion for multiple groups as appropriate.
To determine if NK cells played a role in clearance
RESULTS of HSV-2 from the vaginal mucosa, BALB/c mice were
depleted of NK cells by treatment with anti-asialo GM1IFNg production in mice infected vaginally
antibody prior to genital HSV-2 tk0 inoculation. For com-with HSV-2 tk0
parison, separate groups of mice were control treated
The production of IFNg at the vaginal mucosal surface or made deficient in T lymphocytes by treatment with
following genital inoculation with HSV-2 tk0 was biphasic antibodies to CD4 and CD8 (Fig. 3). No significant differ-
(Fig. 1). The first IFNg peak occurred on Day 2 and fell ences in mean vaginal virus titers were observed among
to low levels on the third day after inoculation. Mice NK cell-depleted, T cell deficient, and control-treated
depleted of NK cells by in vivo treatment with anti-asialo mice for the first 3 days of infection (Day 1, P  0.47;
GM1 antibody produced significantly lower amounts of Day 2, P  0.13; Day 3, P  0.8). However, the mean
IFNg in vaginal secretions on Day 2 than control mice vaginal virus titer in anti-CD4/CD8 antibody-treated mice
treated with PBS or normal rabbit serum (P  0.01) (Fig. was significantly greater than that of the other groups
1). By contrast, Day 2 vaginal IFNg levels in mice de- on Day 4 (P  .05). Further, NK cell-depleted mice and
pleted of T cells were not significantly different than control-treated mice cleared the virus rapidly on Days 5
those of control-treated mice. IFNg levels rose again and 6, whereas virus persisted in vaginal secretions of
after Day 4 in control-treated mice, peaked on Day 5, T cell-deficient mice through at least Day 10.
and fell to low levels on Day 8. IFNg was detected at
comparable levels in NK cell-depleted mice on these Role of CD4/ and CD8/ T cells in IFNg production
days but was undetectable in Day 5 vaginal secretions and clearance of virus from genital mucosa
of T cell-depleted mice and was detected only at very
BALB/c mice were depleted of CD4/ or CD8/ T cellslow levels on Day 6–8 postinoculation.
prior to genital inoculation with HSV-2 tk0 to examine
In vivo neutralization of IFNg results in delayed the importance of these T cell subsets for vaginal IFNg
clearance of vaginal HSV-2 tk0 production and virus clearance from the vaginal mucosa.
Treatment of mice with anti-CD4 antibody resulted inTo examine the role of IFNg in clearance of HSV-2
from the genital mucosa during a primary infection, IFNg altered kinetics of vaginal virus clearance (Fig. 4A). There
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FIG. 1. Detection of IFNg in vaginal secretions following intravaginal HSV-2 tk0 inoculation. Mice were treated with antibodies to CD4 and CD8
(triangles), anti-asialo GM1 (diamonds), or normal rabbit serum (squares) as described under Materials and Methods. Vaginal washes were taken
from BALB/c ANnHsd at 24-hr intervals after genital HSV-2 tk0 inoculation. The concentration of IFNg in vaginal washes was determined by ELISA
(limit of detection 0.5 U/ml). Results are expressed as the mean Units of IFNg/ml //0 SEM for 9 anti-asialo GM1-treated, 5 anti-CD4/CD8-treated,
and 5 normal rabbit sera-treated mice. Less than 0.5 U/ml IFNg were detected in vaginal washes from 8 uninoculated mice (not shown). Comparable
results were obtained in a separate experiment.
was no significant difference in viral titers between anti- Mice depleted of CD8/ T cells by in vivo treatment
with anti-CD8 antibody cleared virus from the vaginalCD4-treated and control-treated mice on Days 1–3 but
virus clearance was delayed and virus persisted in vagi- mucosa and resolved the infection with similar kinetics
as control-treated mice (Fig. 4B). Further, IFNg-secretingnal secretions through Day 8 in anti-CD4-treated mice.
A reduction (87%) in the number of IFNg-secreting cells were detected in the gLN of these mice in numbers
comparable to PBS-treated controls (Table 2) and thecells in the genital lymph nodes (gLN) of anti-CD4-treated
mice as compared to control-treated mice was detected majority of these cells were eliminated by in vitro treat-
ment with anti-CD4 and complement (Table 3).on Day 6 following HSV-2 tk0 infection (Table 2). The
remaining IFNg-secreting cells from these mice were
predominantly CD8/ as treatment of gLN lymphocytes DISCUSSION
from these mice with anti-CD8 antibody and complement
resulted in nearly complete (88%) depletion of IFNg-se- The immune mechanisms directly responsible for virus
clearance are not well understood and may depend oncreting cells (Table 3). Treatment of the same population
of cells with anti-CD4 antibody and complement did not variables such as the virus type, dose, and route of inocu-
lation. Historically, virus-specific CD8/ T cells have beenfurther reduce the number of IFNg-secreting cells.
TABLE 1
Neutralization of IFNg in Vaginal Secretions by in Vivo Treatment with Anti-IFNg Antibody
Days post vaginal inoculation
1 3 5 7 9
In vivo treatment IFNg units/ml (mean { SEM)a
Control treated 5.6 { 3.3 0.92 { 0.37 33.0 { 6.0 4.3 { 1.2 0.5
Anti-IFNg treated 0.5b 0.5 0.5 0.5 0.5
a Results are expressed as the mean IFNg Units/ml present in vaginal washes from 6 PBS or anti-IFNg antibody treated, HSV-2 tk0 inoculated
BALB/c mice.
b Limit of detection for this assay was 0.5 Units/ml. IFNg content of vaginal washes from uninoculated BALB/c mice was less than 0.5 Units/ml.
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FIG. 2. Effect of in vivo neutralization of IFNg on clearance of virus during an acute vaginal HSV-2 tk0 infection. Six BALB/c AnNHsd mice were
treated with anti-IFNg (squares) or control (diamonds) beginning the day prior to inoculation (A) or 3 days following (B) intravaginal HSV-2 tk0
inoculation. The data are presented as the mean vaginal virus titer (log 10) //0 SEM and are representative of two repetitions of each experiment.
Data points indicated with an asterisk are significantly different than control values (P  0.004 for A and P  0.035 for B).
credited with virus clearance via direct cytolysis of in- secreted factors such as IFNg mediating clearance of
viruses such as vaccinia virus (Ruby and Ramshaw, 1991;fected cells (Zinkernagel and Doherty, 1979; Lukacher et
al., 1984). However, evidence has also been reported for Huang et al., 1993), ectromelia virus (Karupiah et al.,
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FIG. 3. Kinetics of HSV-2 tk0 clearance from the genital tracts of NK cell-depleted or T cell deficient mice. Mice were treated with PBS (X) or
normal rabbit sera (squares) as controls or treated with antibody to deplete either T cells (triangles) or NK cells (diamonds) and then inoculated
vaginally with HSV-2 tk0. The data are presented as the mean vaginal virus titer (log 10) //0 SEM from the mice used in Fig. 1. Data points in the
anti-CD4/CD8-treated group indicated with an asterisk are significantly different (P  0.05) from values in normal rabbit sera-treated group. A
representative experiment of two performed is shown.
1993), murine cytomegalovirus (Lucin et al., 1992), and which develop following HSV-2 infection (Jennings et
al., 1985), presumably due to the ability of HSV-2 toHSV-1 (Smith et al., 1994). The results of the present
study demonstrate that IFNg augments T cell-mediated decrease the surface expression of MHC class I mole-
cules (Jennings et al., 1985; York et al., 1994).virus clearance but is not essential for the ultimate clear-
ance of HSV-2 from the vaginal epithelia. Depletion of NK cells with the consequent loss of early
IFNg production (Fig. 1) did not significantly affect theDuring the first 3 days of infection, IFNg was appar-
ently produced predominantly by NK cells while IFNg rate of HSV-2 clearance from the vagina (Fig. 3). In con-
trast, neutralization of IFNg beginning Day 3 after inocu-detected on Days 4 – 7 was produced primarily by T
cells (Fig. 1). Because greater numbers of IFNg secre- lation effectively delayed virus clearance (Fig. 2B), sug-
gesting that CD4/ T cell-derived IFNg and not NK cell-ting cells were detected in genital lymph nodes from
CD8/, compared to CD4/ T cell-depleted mice (Tables produced IFNg played a role in rapid virus clearance.
NK cell-produced IFNg has been shown to play an im-2 and 3), and CD4/ T cell depletion, but not CD8/ T
cell depletion, resulted in low levels of IFNg in vaginal portant role in skewing the developing immune response
to a Th1-type response in Leishmania major infectionssecretions on Days 4 – 5 (G. Milligan, unpublished re-
sults), it seems most likely that Th1-type CD4/ T cells (Scharton and Scott, 1993). However, in preliminary ex-
periments, depletion of NK cells resulted in severe damp-were primarily responsible for the second period of
IFNg-secretion. These data are in agreement with our ening of early IFNg release but did not change the ratio
of IFNg secreting T cells to IL-4 secreting T cells follow-previous studies, demonstrating the appearance of
HSV-specific, Th1-type CD4/ T cells in vaginal tissue ing HSV-2 tk0 vaginal inoculation (G. Milligan, unpub-
lished results). Therefore, in these studies of a primaryon Day 5 after infection (Milligan and Bernstein, 1995a)
but differ from those of Smith et al. (1994) in which HSV-2 infection we could not detect a role for NK cells
in virus clearance from the vagina or in influencing theeither CD4/ or CD8/ T cells apparently could provide
the IFNg required for clearance of HSV-1 in a cuta- nature of the developing HSV-specific CD4/ T cell re-
sponse. It remains possible that NK cells may have influ-neous infection model. The failure of CD8/ T cell
depletion to affect virus clearance kinetics (Fig. 4B) as enced the local vaginal immune response in other ways.
For example, based on the ability of IFNg to enhancewell as the meager CD8/ T cell response to HSV-2 in
this model (Milligan and Bernstein, 1995a) may reflect expression of antigens such as mouse endothelial cell
antigen 325 (Duijvestijn et al., 1986), intercellular adhe-low numbers of HSV-specific CD8/ T cell precursors
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FIG. 4. Clearance of virus from the genital mucosa of mice deficient in CD4/ or CD8/ T cells. Groups of 5 mice were control-treated (diamonds)
or treated with anti-CD4 antibody (squares) (A) or anti-CD8 antibody (squares) (B) and inoculated intravaginally with HSV-2 tk0. In A, data points
indicated by an asterisk are significantly different than control-treated values (P  0.002). The data from representative experiments of two performed
for each antibody treatment are presented as the mean vaginal virus titer (log 10) //0 SEM.
sion molecule 1 (ICAM 1), and platelet endothelial cell prevent, virus clearance (Figs. 2A and 2B). Similar re-
sults were obtained using BALB/c mice with a targetedadhesion molecule 1 (PECAM1) on high endothelial ve-
nules (Tang and Hendricks, 1996), it is possible that NK- deletion of the IFNg gene (IFNg 0/0) where the delay
of clearance was approximately 1 day as comparedproduced IFNg may play a role such as enhancing re-
cruitment of lymphocytes and inflammatory cells into the to control animals (G. Milligan, unpublished results).
These results are different than those obtained byinfected mucosa.
Neutralization of IFNg in vivo delayed, but did not Smith et al. (1994) and Bouley et al. (1995) in which in
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TABLE 2 agent. Alternatively, cytokines capable of acting in syn-
ergy with IFNg such as TNFa may have been presentEffect of Anti-CD4 or Anti-CD8 Antibody Treatment in Vivo on the
in sufficient concentration at the mucosal surface onlyNumber of IFNg Secreting Cells in Genital Lymph Nodes (gLN) of
HSV-2 tk0 Inoculated Mice later in the infection after the arrival of T cells and macro-
phages.
In vivo treatment IFNg secreting cells/gLNa A significant portion of the inflammatory exudate cells
found in the vagina following intravaginal inoculation ofExperiment 1b
HSV-2 tk0 was composed of macrophages (G. Milligan,PBS treated 7415 { 2728
Anti-CD4 treated 962 { 313c unpublished results). Macrophages activated by IFNg
Uninoculated, untreated 29 release a number of antimicrobial compounds including
Experiment 2 nitrogen metabolites and TNFa (Nathan, 1987; Ding et
PBS treated 8528 { 1279
al., 1988). The ability of nitric oxide to inhibit HSV infectionAnti-CD8 treated 7474 { 1502d
in vitro (Croen, 1993) and TNFa administration to in-Uninoculated, untreated 7
crease survival of HSV-1-infected mice (Rossol-Voth et
a Genital lymph nodes were removed on Day 6 following HSV-2 tk0 al., 1991) suggest that these molecules may have contrib-
inoculation. Results are expressed as the mean number of IFNg secre- uted to resolution of the vaginal infection in this model.
ting cells per gLN { SEM (Experiment 1, n  3 control, 4 anti-CD4-
Studies to determine the role of vaginal macrophagestreated mice; Experiment 2, n  4 control and 4 anti-CD8-treated mice).
and their products in the protection of the vaginal mucosab Results are from a single representative experiment of three per-
formed for Experiment 1 and two for Experiment 2. Results of uninocu- are in progress.
lated, untreated gLN analysis are from a single animal. Depletion of both CD4/ and CD8/ T cells resulted
c The number of IFNg secreting cells from anti-CD4-treated mice is in persistent virus shedding through Day 10 (Fig. 3),
significantly less than from control treated mice (P  0.02).
suggesting an essential role for T cells in virus clear-d The number of IFNg secreting cells from anti-CD8-treated mice is
ance from the vagina. Depletion of only CD8/ T cellsnot significantly different from control treated mice (P  0.61).
had no affect on virus clearance, whereas clearance
was delayed, but not prevented by depletion of CD4/
T cells (Figs. 4A and 4B). It seems very likely that CD8/vivo neutralization of IFNg or genetic deletion of IFNg
prevented clearance of HSV-1 from the skin or the eye, T cells were responsible for virus clearance in CD4/
T cell-depleted mice because IFNg-secreting CD8/ Trespectively. Although the difference in requirement
for IFNg in viral clearance among these studies may cells were detected in CD4/ T cell-depleted mice (Ta-
bles 2 and 3) and mice depleted of both T cell subsetsreflect a difference in sensitivities of HSV-2 and HSV-
1 to direct or indirect effects of IFNg, it is also possible shed virus through Day 10 (Fig. 3). Taken together,
these results are consistent with the hypothesis thatthat the disparate results reflect only a difference in
viral clearance kinetics. That is, virus might have ulti- both T cell subsets can effect virus clearance during
an acute HSV-2 vaginal infection but that CD4/ T cellsmately been cleared in the studies of Smith et al. (1994)
and Bouley et al. (1995) but at times later than were
assayed. It is also possible that other cytokines capa-
TABLE 3ble of replacing the function of IFNg or different clear-
ance mechanisms with different dependencies on Surface Phenotype of IFNg Secreting Lymphocytes from the gLN of
IFNg may predominate at certain anatomical sites. Anti-CD4 or Anti-CD8 Antibody Treated, HSV-2 tk0 Inoculated Mice
Although it can be envisioned that IFNg in vaginal
Treatment in vitrosecretions may act on epithelial cells at the surface of
the vaginal lumen as well as on immune cells in the
C Anti-CD4 / C Anti-CD8 / C
vaginal exudate to enhance antigen processing and pre- Treatment
sentation and immune effector cell function, the impor- in vivoa IFNg secreting cells/106 mononuclear cellsb
tance and role of IFNg at this site relative to that present
Control 309 { 8 80 { 3 (74.1%) 279 { 72 (9.7%)throughout the cell layers of the mucosa remains to be
Anti-CD4 75 { 31 82 { 32 (0%) 9 { 7 (88%)ascertained. IFNg may act alone on vaginal epithelial
Anti-CD8 164 { 5 5 { 3 (96.9%) 191 { 6 (0%)
cells (Kimura et al., 1994; Klotzbucher et al., 1990) or in
synergy with other cytokines such as TNFa, IFNa, or a Groups of 4 BALB/c mice were treated in vivo with PBS (Control),
anti-CD8 (2.43), or anti-CD4 (GK1.5) as described under Materials andIFNb (Feduchi and Carrasco, 1991; Balish et al., 1992;
Methods. Genital lymph node cells were harvested on Day 6 afterCzarniecki et al., 1984; Zerial et al., 1982) to exert direct
inoculation, pooled, and treated in vitro as indicated.antiviral effects. The presence of vaginal IFNg in the b Results are expressed as the mean number of IFNg secreting cells/
absence of a detectable effect on virus clearance during 106 mononuclear cells{ SD. The percentage of inhibition of the number
the first 3 days of primary infection (Table 1, Fig. 2) would of IFNg secreting cells by a given in vitro treatment is given in parenthe-
ses.seem to argue against IFNg acting directly as an antiviral
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1 replication by tumor necrosis factor and interferon g. Virology 180,appear to play the dominant role in a normal animal.
822–825.CD4/ cytotoxic lymphocytes (CTL) and smaller num-
Huang, S., Hendriks, W., Althage, A., Hemmi, S., Bluethmann, H., Kam-bers of CD8/ CTL have been demonstrated in the imo, R., Vilcek, J., Zinkernagel, R. M., and Aguet, M. (1993). Immune
draining lymph nodes of mice infected intravaginally response in mice that lack the interferon-g receptor. Science 259,
with HSV-2 tk0 (Milligan and Bernstein, 1995a). IFNg 1742–1745.
Jennings, S. R., Rice, P. L., Kloszewski, E. D., Anderson, R. W.,may have augmented T cell recognition of HSV-2-in-
Thompson, D. L., and Tevethia, S. S. (1985). Effect of herpes sim-fected cells and enhanced HSV-specific CTL function
plex virus types 1 and 2 on surface expression of class I majorby increasing the expression of both class I and class
histocompatibility complex antigens on infected cells. J. Virol. 56,
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